Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry J Fry

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
Molecular Cancer Therapeutics|February 26, 2021
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T CellsAlka Dwivedi, Atharva Karulkar, Sarbari Ghosh, et al.
The Journal of Experimental Medicine|June 25, 2008
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsetsClaude Sportès, Frances T Hakim, Sarfraz A Memon, et al.
JCI Insight|June 9, 2026
Reduced CCL/Be-specific CD4+ T cells in CCL3-deficient or peptide-MHC II CAR-T cell-treated miceMichael T Falta, Masoom Raza, Caley J Nevienski, et al.
The Journal of Clinical Investigation|September 14, 2020
Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patientsKazusa Ishii, Marie Pouzolles, Christopher D Chien, et al.
Nature Medicine|November 21, 2017
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapyTerry J Fry, Nirali N Shah, Rimas J Orentas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2020
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialNirali N Shah, Steven L Highfill, Haneen Shalabi, et al.
Journal for Immunotherapy of Cancer|June 5, 2026
CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial resultsSara K Silbert, Flavia Gava, Bonnie Yates, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 22, 2018
Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single InstitutionRicardo Melendez-Munoz, Rachel Marchalik, Theresa Jerussi, et al.
Nature Medicine|October 3, 2018
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cellMarco Ruella, Jun Xu, David M Barrett, et al.
Journal for Immunotherapy of Cancer|December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse eventsMarcela V Maus, Sara Alexander, Michael R Bishop, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Molecular Cancer Therapeutics|February 26, 2021
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T CellsAlka Dwivedi, Atharva Karulkar, Sarbari Ghosh, et al.
The Journal of Experimental Medicine|June 25, 2008
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsetsClaude Sportès, Frances T Hakim, Sarfraz A Memon, et al.
JCI Insight|June 9, 2026
Reduced CCL/Be-specific CD4+ T cells in CCL3-deficient or peptide-MHC II CAR-T cell-treated miceMichael T Falta, Masoom Raza, Caley J Nevienski, et al.
The Journal of Clinical Investigation|September 14, 2020
Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patientsKazusa Ishii, Marie Pouzolles, Christopher D Chien, et al.
Nature Medicine|November 21, 2017
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapyTerry J Fry, Nirali N Shah, Rimas J Orentas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2020
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialNirali N Shah, Steven L Highfill, Haneen Shalabi, et al.
Journal for Immunotherapy of Cancer|June 5, 2026
CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial resultsSara K Silbert, Flavia Gava, Bonnie Yates, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 22, 2018
Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single InstitutionRicardo Melendez-Munoz, Rachel Marchalik, Theresa Jerussi, et al.
Nature Medicine|October 3, 2018
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cellMarco Ruella, Jun Xu, David M Barrett, et al.
Journal for Immunotherapy of Cancer|December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse eventsMarcela V Maus, Sara Alexander, Michael R Bishop, et al.
Pageof 13